Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 6 ordered label revisions for the lung cancer drugs Rybrevant (amivantamab) and Lazcluze (lazertinib), and the anticoagulant Eliquis (apixaban), citing bleeding risks associated with their combined use. Apixaban is administered…
To read the full story
REGULATORY
- Japan Cabinet Approves Food Tax Cut Outline; 1% Rate for 2 Years
September 16, 2026
- MHLW to Track Prescription Shifts under OTC-Like Drug Charge
September 16, 2026
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…